Literature DB >> 8053954

Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome.

A Gough1, J Faint, M Salmon, A Hassell, P Wordsworth, D Pilling, A Birley, P Emery.   

Abstract

OBJECTIVE: To test the hypothesis that genetic characterization of patients at the time they present with inflammatory arthritis can predict subsequent destructive disease.
METHODS: We evaluated 177 patients with early arthritis. Patients were serologically tested for rheumatoid factor (RF) and were DNA oligotyped for the presence of conserved base sequences in the third hypervariable region (HVR3) of the DRB1 gene, previously shown to be associated with severe rheumatoid arthritis (RA). Homozygosity in the patient's genotype was confirmed using restriction fragment length polymorphism analysis. The main outcome measure was radiologic erosions at 1 year.
RESULTS: At presentation, 120 patients fulfilled the American College of Rheumatology 1987 criteria for RA, 64% of whom possessed the conserved base sequences, compared with 45% of 347 healthy controls (P < 0.001) and with 56% of 57 patients with other inflammatory arthritis (P not significant). Within the RA population, the frequency of Dw4/Dw14 compound heterozygotes was disproportionately increased. The presence of either HVR3 or RF had a relative risk of 13.49 for erosions, with a sensitivity of 95% (specificity 39%); the presence of both HVR3 and RF had a relative risk of 8.13, with a specificity of 88% (sensitivity 53%). All but 1 patient with the Dw4/Dw14 genotype developed erosions within 1 year.
CONCLUSION: Knowledge of a patient's HLA-DR type and RF status allows clinically useful prediction of erosive disease; patients possessing Dw4/Dw14 represent a particularly high-risk subgroup.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053954     DOI: 10.1002/art.1780370809

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  34 in total

Review 1.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

Review 2.  Combination therapy in rheumatoid arthritis.

Authors:  S Bingham; P Emery
Journal:  Springer Semin Immunopathol       Date:  2001

3.  HLA-DRB1 gene transcripts in rheumatoid arthritis.

Authors:  S Kerlan-Candon; B Combe; R Vincent; J Clot; V Pinet; J F Eliaou
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

4.  Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study.

Authors:  A Stockman; B D Tait; R Wolfe; C A Brand; M J Rowley; M D Varney; R Buchbinder; K D Muirden
Journal:  Rheumatol Int       Date:  2005-09-07       Impact factor: 2.631

Review 5.  Treatment of rheumatoid arthritis.

Authors:  Paul Emery
Journal:  BMJ       Date:  2006-01-21

Review 6.  Should patients with recent onset rheumatoid arthritis be offered genetic screening?

Authors:  D P Symmons; W E Ollier; P Brennan; A J Silman
Journal:  Ann Rheum Dis       Date:  1996-07       Impact factor: 19.103

7.  Algorithm to predict radiological erosions in early rheumatoid arthritis. Messages from paper are incorrect.

Authors:  P Emery; A Gough; J Devlin; M Green
Journal:  BMJ       Date:  1996-11-30

8.  Should patients with recent onset of rheumatoid arthritis be offered genetic screening?

Authors:  P Emery; M Salmon; J Gooi
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

9.  Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy.

Authors:  T Möttönen; L Paimela; M Leirisalo-Repo; H Kautiainen; J Ilonen; P Hannonen
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

10.  Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.

Authors:  L Gossec; M Dougados; P Goupille; A Cantagrel; J Sibilia; O Meyer; J Sany; J-P Daurès; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.